What Does Semler Scientific (SMLR) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Full Guide
Semler Scientific (SMLR) supplies specialized medical devices that aid in the early diagnosis of peripheral arterial disease, solidifying its position in the healthcare market. Backed by innovative software capabilities, the company has posted steady revenue growth and positive earnings, suggesting a promising stock outlook.
Subscribe🏢 What kind of company is Semler Scientific?
Semler Scientific is a leading healthcare partner that develops intuitive Point-of-Care diagnostic solutions designed to help uncover and prevent hidden chronic diseases in patients within complex medical environments.
The company's flagship product, 'QuantaFlo,' is an integrated software and hardware system that quickly and non-invasively measures arterial blood flow in the limbs to diagnose peripheral arterial disease. It is primarily offered on a subscription basis to medical providers affiliated with insurance companies.
How does Semler Scientific make money?| Business Segment | Revenue Share | Description |
|---|---|---|
| Software Licenses | Core | Recurring software license fees paid by medical institutions and insurers to use the QuantaFlo system |
| Equipment Rental and Sales | Supplementary | Revenue generated from the rental or one-time sale of diagnostic hardware sensors and related equipment |
The overwhelming majority of operating profit is generated from recurring subscription revenue of QuantaFlo software licenses. As U.S. health insurers operating large Medicare Advantage plans experience tangible savings from early diagnosis, the rate of adoption for this solution continues to climb, producing a clearly structural cash flow profile.
📐 Semler Scientific market cap and company size
Market capitalization stands at $310.9M, and the company employs 79 people people.
Years of accumulated clinical data and FDA approvals form a durable regulatory moat that competitors cannot easily breach. A broad platform network with tens of thousands of diagnostic systems deployed across clinics throughout the United States is a distinct intangible asset that enables the instant rollout of new software updates and add-on services.
📈 Semler Scientific outlook and stock price trends
1-Year Price Performance
Analyst Consensus
52-Week Price RangeThe structural rise of the elderly population in the United States and shifts in health insurance policies that encourage the prevention of chronic diseases are expected to drive broad, long-term adoption of the diagnostic system. However, the excessively high revenue dependence on a single product (QuantaFlo), a customer base concentrated among a small number of large insurance carriers, and the potential for policy changes by medical device regulators are key variables to scrutinize closely when making investment decisions.
- Maximizing recurring revenue by expanding QuantaFlo system usage among existing insurance customers and lifting renewal rates
- Developing and launching new software solutions capable of diagnosing cardiovascular conditions beyond peripheral arterial disease
⚔️ Semler Scientific core strengths and risks
The company has established a high-margin recurring revenue model through its excellent early-diagnostic solution, but with heavy dependence on a single product and a small set of customers, it remains exposed to revenue volatility.
💪 Core Strengths
⚠️ Core Risks
🔄 Semler Scientific competitors and related (beneficiary) stocks
In the digital healthcare and chronic disease diagnostics market, the company competes with IRTC and other providers of similar cardiovascular monitoring solutions as well as non-invasive diagnostic device makers for a limited medical budget. In a broader medical device context, it is also widely grouped with healthcare-related stocks such as large equipment manufacturers MDT and SYK.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 IRTC | iRhythm Holdings Inc | $123.07 | -0.3% | $4.1B | - | 21.8 | -9.63% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| MDT | Medtronic Plc | $94.17 | +1.1% | $120.5B | 23.2 | 2.4 | 10.66% | 3.07% |
| SYK | Stryker Corp | $303.13 | -1.6% | $116.3B | 31.4 | 4.8 | 16.51% | 1.17% |
✅ Semler Scientific investor checkpoints
Listed on a U.S. exchange, Semler Scientific supplies essential diagnostic software that intuitively uncovers hidden chronic diseases in an aging society, shifting the healthcare market paradigm from treatment to prevention.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| Customer Diversification | The pace at which revenue concentration among a few top customers is diversified and new small and mid-sized hospital/clinic accounts are secured | Continued monitoring warranted |
| New Product Launches | Successful commercialization of the pipeline to follow QuantaFlo and any additional FDA approvals | To be confirmed |
| Reimbursement Policy Changes | Shifts in U.S. health authorities' stance on Medicare Advantage reimbursement rates and preventive medicine support policies | Key observation factor |
Unannounced changes in specific healthcare policies or the failure to renew license agreements with key large customers are important volatility factors that could impair the company's annual earnings and operating margins.
For value investors who prefer proven diagnostic technology and a high-margin software business model and have a keen interest in the preventive medicine theme of the aging era, the stock can be recommended as a valid long-term portfolio alternative.
Subscribe Today's 5 AI picks, all free